LifeScience Data Mining and Visualization Market Report 2025

The life science data mining and visualization market size has grown rapidly in recent years. It will grow from $3.71 billion in 2024 to $4.21 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period is attributed to the increasing adoption of electronic health records, expansion of genomics and proteomics research, growing integration of AI and machine learning, rising demand for real-time clinical insights, and heightened focus on big data analytics in healthcare.

The life science data mining and visualization market size is expected to see rapid growth in the next few years. It will grow to $6.85 billion in 2029 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period is driven by increased use of bioinformatics tools, higher generation of clinical trial data, growing collaborations between pharmaceutical and technology companies, advancements in imaging and visualization technologies, and a stronger emphasis on data-driven drug discovery. Key trends in the forecast period include progress in AI-driven analytics, development of cloud-based data platforms, innovation in real-time visualization tools, advancement in multi-omics data integration, and growth in predictive modeling techniques.

The increasing demand for personalized medicine is expected to drive the growth of the life science data mining and visualization market. Personalized medicine involves tailoring medical treatment to an individual’s genetic profile, lifestyle, and environmental factors to provide more accurate and effective care. This demand is growing because personalized approaches enable targeted therapies that improve patient outcomes while reducing the likelihood of adverse effects. Life science data mining and visualization plays a key role in supporting personalized medicine by converting complex patient data into actionable insights that guide precise and individualized treatment strategies. For example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the United States, reported that in 2023, the United States Food and Drug Administration approved sixteen new personalized treatments for patients with rare diseases, a significant increase from six approvals in 2022. As a result, the rising interest in personalized medicine is fueling the expansion of the life science data mining and visualization market.

Leading companies in the life science data mining and visualization market are developing advanced solutions such as Platform-as-a-Service offerings to unify real-world data sources, enhance analytics, and deliver interactive visualization tools that support efficient, data-driven decision-making across clinical, research, and commercial functions. Platform-as-a-Service refers to a cloud-based environment that provides users with the tools, infrastructure, and services needed to build, deploy, and manage applications without the need to oversee the underlying hardware or software. For example, in February 2025, CitiusTech, a health information technology company based in the United States, introduced CitiusTech HealthSPARX, an integrated platform designed for life sciences organizations to simplify data management and accelerate insight generation through advanced, artificial intelligence-powered analytics. HealthSPARX supports integration of various datasets, enables regulatory-compliant analytics, and promotes collaborative decision-making across departments such as clinical research and commercial strategy.

In July 2024, Thermo Fisher Scientific Inc., a science-focused company based in the United States, acquired Olink Holding AB (publ) for approximately three point one billion United States dollars. This acquisition is aimed at incorporating Olink’s expertise in proteomics and biomarker discovery into Thermo Fisher’s broader research and clinical diagnostics portfolio. The integration is expected to strengthen the company’s capabilities in life sciences and enhance outcomes in scientific research. Olink Holding AB is a life sciences company based in Sweden that specializes in proteomics and biomarker data analysis.

Major players in the lifescience data mining and visualization market are Microsoft Corporation, F. Hoffmann-La Roche Ltd., Oracle Corporation, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, SAP SE, Amgen Inc., GE Healthcare, IQVIA Holdings Inc., ICON plc, Agilent Technologies Inc., Dassault Systèmes SE, OpenText Corporation, Illumina Inc., Veeva Systems Inc., Palantir Technologies Inc., QIAGEN N.V., Flatiron Health Inc., LabWare Inc., Medable Inc.

North America was the largest region in the lifescience data mining and visualization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lifescience data mining and visualization report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lifescience data mining and visualization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Life science data mining and visualization refers to the process of identifying meaningful patterns, relationships, and insights from large and complex biological and clinical datasets and presenting them in clear, interpretable visual formats. Its objective is to accelerate scientific discovery, enhance decision-making in research and healthcare, and provide a deeper understanding of diseases, drug responses, and biological systems.

The primary component types of life science data mining and visualization are software and services. Software includes specialized tools and platforms designed to extract, analyze, and visually represent complex biological, clinical, and genomic data to support research insights and decision-making. These solutions use technologies such as machine learning algorithms, artificial intelligence, natural language processing, data visualization tools, and statistical analysis software, and are deployed via on-premises solutions, cloud-based platforms, hybrid models, software as a service (SaaS), and platform as a service (PaaS). Applications include drug discovery, genomics and genetic research, clinical data analysis, patient health monitoring, and epidemiology studies. Key end-users include pharmaceutical companies, biotechnology firms, clinical research organizations (CROs), healthcare providers, and research and academic institutions.

The life science data mining and visualization market research report is one of a series of new reports that provides life science data mining and visualization market statistics, including the life science data mining and visualization industry global market size, regional shares, competitors with the life science data mining and visualization market share, detailed life science data mining and visualization market segments, market trends, and opportunities, and any further data you may need to thrive in the life science data mining and visualization industry. This life science data mining and visualization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The life science data mining and visualization market consists of revenues earned by entities by providing services such as training and support services for analytics platforms, custom visualization development services, and managed services for cloud-based platforms. The market value includes the value of related goods sold by the service provider or included within the service offering. The life science data mining and visualization market also includes sales of data integration platforms, bioinformatics pipelines, real-time monitoring platforms, and collaborative research portals. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The Life Science Data Mining and Visualization market is segmented by application, end-user, technology, data source, deployment mode, component, type, and product & services.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.